James R Rusche Net Worth

The estimated Net Worth of James R Rusche is at least $15.7 Million dollars as of 15 May 2015. James Rusche owns over 15,000 units of Repligen stock worth over $13,888,147 and over the last 21 years James sold RGEN stock worth over $1,859,027.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

James Rusche RGEN stock SEC Form 4 insiders trading

James has made over 18 trades of the Repligen stock since 2005, according to the Form 4 filled with the SEC. Most recently James sold 15,000 units of RGEN stock worth $619,800 on 15 May 2015.

The largest trade James's ever made was exercising 50,000 units of Repligen stock on 7 August 2013 worth over $293,500. On average, James trades about 13,522 units every 138 days since 2004. As of 15 May 2015 James still owns at least 96,849 units of Repligen stock.

You can see the complete history of James Rusche stock trades at the bottom of the page.

What's James Rusche's mailing address?

James's mailing address filed with the SEC is C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453.

Insiders trading at Repligen

Over the last 22 years, insiders at Repligen have traded over $118,224,292 worth of Repligen stock and bought 160,440 units worth $1,459,521 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Glenn P Muir, and Walter C Herlihy. On average, Repligen executives and independent directors trade stock every 33 days with the average trade being worth of $3,015,702. The most recent stock trade was executed by Ralf Kuriyel on 2 August 2024, trading 7,148 units of RGEN stock currently worth $1,139,034.

What does Repligen do?

repligen corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. we are a leading manufacturer of protein a, a critical reagent used to manufacture monoclonal antibody-based therapeutics. we also supply several growth factor products used to increase cell culture productivity in biomanufacturing. in the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of opus™ (open platform user specified) single-use chromatography columns used in the biologics purification process. repligen’s corporate headquarters are located in waltham, ma, usa; we have an additional manufacturing facility in lund, sweden.

Complete history of James Rusche stock trades at Repligen

Repligen executives and stock owners

Repligen executives and other stock owners filed with the SEC include:

• Anthony Hunt,
  President, Chief Executive Officer, Director
• Jon Snodgres,
  Chief Financial Officer
• Ralf Kuriyel,
  Senior Vice President - Research and Development
• Anthony J. Hunt,
  CEO, Pres & Director
• Jon K. Snodgres,
  Chief Financial Officer
• Ralf Kuriyel,
  Sr. VP of R&D
• Karen Dawes,
  Independent Chairperson of the Board
• Glenn Muir,
  Independent Director
• Thomas Ryan,
  Independent Director
• Nicolas Barthelemy,
  Independent Director
• Rohin Mhatre,
  Independent Director
• Carrie Eglinton,
  Director
• James Slaughter,
  Chief HR Officer
• James R. Bylund,
  Chief Operating Officer
• Christine Gebski,
  Sr. VP of Filtration & Chromatography
• Ken Elmer,
  Global Head of HR
• Rachel Goodrich,
  VP of Marketing
• Stephen Tingley,
  VP of Global Sales
• Squire Servance,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Sondra S. Newman,
  Global Head of Investor Relations
• Jim Bylund,
  Sr. VP of Operations & Information Technology
• Jason K Garland,
  CFO
• Glenn L Md Cooper,
  Director
• James R Rusche,
  Senior Vice President
• John Cox,
  Director
• Howard Benjamin,
  
• Roy T Eddleman,
  10% owner
• Christine Gebski,
  See Remarks
• G William Miller,
  Director
• Timothy Scott Harris,
  
• Barbara Burnim Day,
  Vice President
• Daniel W Muehl,
  CFO
• Partners L P/Ilbiotechnolog...,
  
• Alfred Lewis Goldberg,
  Director
• Walter C Herlihy,
  PRESIDENT, CEO
• Michael A Griffith,
  Director
• Daniel P Witt,
  Vice President
• Jonathan I Lieber,
  CFO
• Earl Webb Henry,
  Director
• William J Kelly,
  Vice President
• Alexander Rich,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Hal Landy,
  Vice President
• Paul Schimmel,
  Director
• Laura Whitehouse,
  Vice President
• Robert J Hennessey,
  Director
• Margaret Pax,
  
• Konstantin Konstantinov,
  
• Martin D Madaus,
  
• James Bylund,
  Chief Operating Officer
• Olivier Loeillot,
  Chief Executive Officer